utated gene, and then re-administers the stem cells back into the patients. While many clinical trials have succeeded, some ended tragically when the virus ended up activating a cancer-causing gene. Because of this, the Food and Drug Administration is not currently approving any gene-therapy clinical trials.
"If, before the stem cells have been re-introduced into the patients, the physicians could first multiply them in the lab, they could then run assays determining if the virus has landed in any undesirable places," says Lodish. "They could then discard those bad cells, and only administer the good ones to the patients."
But most importantly, these findings aid basic research. "We want to know all sorts of things, like what genes are active in this stem cell, or how this stem cell decides to develop into one kind of cell as opposed to another," says Lodish.
Lodish and his colleagues are collaborating with researchers at Lund University in Sweden to repeat these results with human cord blood.
'"/>Source:
Whitehead Institute for Biomedical Research
Page: 1 2 3 Related biology news :1.
Powerful new tool for studying brain development2.
Powerful genome ID method extended to humans3.
New lab technique identifies high levels of pathogens in therapy pool4.
Brain-mapping technique aids understanding of sleep, wakefulness5.
Study reveals new technique for fingerprinting environmental samples6.
Researchers pioneer new gene therapy technique using natural repair process7.
Newer imaging techniques may lead to over-treatment8.
Gene silencing technique offers new strategy for treating, curing disease9.
Mosaic mouse technique offers a powerful new tool to study diseases and genetics10.
Researchers devise new technique for creating human stem cells11.
New technique rapidly detects illness-causing bacteria